Chicago—Targeted therapies for the treatment of certain cancers garnered keen interest during the American Society of Clinical Oncology's (ASCO’s) annual meeting here in June.
Researchers are studying targeted therapies for non–small cell lung cancer (left). Preliminary findings of a targeted therapy that inhibits a tumor-specific protein called anaplastic lymphoma kinase (ALK) showed promise in an expanded phase 1 study in treating patients with ALK-positive non–small cell lung tumors.
Graphic Jump Location
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 1
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
The Rational Clinical Examination
Make the Diagnosis: Melanoma
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.